Tissue Factor Science
Iconic Therapeutics is leveraging its deep insight into the role of tissue factor in inflammation and angiogenesis to develop breakthrough medicines for ophthalmology and oncology indications.
Ophthalmology
With our investigational tissue factor therapeutics, we are pursuing promising opportunities to modify grievous diseases in ophthalmology, including wet age-related macular degeneration (AMD).
Oncology
While tissue factor (TF) overexpression itself is not oncogenic, it facilitates key processes that lead to the development and progression of tumors. We are exploring potential therapeutic agents that target TF across a broad range of solid tumors.
Recent News
August 22, 2019: Iconic Therapeutics Signs Ophthalmology Option Agreement
May 16, 2019: Iconic Therapeutics and Exelixis enter into an exclusive option and license agreement for ICON-2
May 14, 2019: Iconic Therapeutics Enters Licensing Agreement with Zymeworks for ZymeLinkTM Antibody-Drug Conjugate Platform